156 related articles for article (PubMed ID: 34563457)
1. Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma.
Taenaka R; Takigawa K; Okamura K; Obara T; Nishimura N; Kohno K; Aoki K; Ogawa R
Transfus Apher Sci; 2021 Dec; 60(6):103279. PubMed ID: 34563457
[TBL] [Abstract][Full Text] [Related]
2. First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.
Bekadja MA; Mansour B; Ouldjeriouat H; Entasoltan B; Bouchama S; Charef L; Amani K; Hakiki N; Bouamama F; Osmani S; Brahimi M; Arabi A; Bouhass R; Yafour N
Transfus Apher Sci; 2021 Jun; 60(3):103070. PubMed ID: 33612450
[TBL] [Abstract][Full Text] [Related]
3. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.
Prakash VS; Malik PS; Sahoo RK; Pramanik R; Choudhary P; Varshney AN; Kumar L
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):44-51. PubMed ID: 34452863
[TBL] [Abstract][Full Text] [Related]
4. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH).
Cid J; Monsalvo S; Castillo C; Pascual C; Moreno-Jiménez G; López-Parra M; Andón C; Guerra L; Esquirol A; Sánchez-Ortega I; Ortega S; Zalba S; Martínez C; Rovira M; Marín P; Lozano M;
Transfus Apher Sci; 2021 Apr; 60(2):103052. PubMed ID: 33483284
[TBL] [Abstract][Full Text] [Related]
5. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
Malinowska I; Romiszewski M; Smalisz K; Stelmaszczyk-Emmel A; Nasilowska-Adamska B; Krol M; Urbanowska E; Brozyna A; Baginska-Dembowska B
Transfus Apher Sci; 2021 Jun; 60(3):103077. PubMed ID: 33583716
[TBL] [Abstract][Full Text] [Related]
7. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients.
Antelo ML; Altuna A; Gimeno JJ; Ferreiro JJ; Amunárriz C; Mateos JJ; Zalba S; Alkorta A; Rifón J; Arroyo JL; Uresandi A; Moreno JA; Nájera MJ; Pinzón S; García A; Vallejo JC;
Transfus Apher Sci; 2021 Jun; 60(3):103130. PubMed ID: 33840626
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
[TBL] [Abstract][Full Text] [Related]
9. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
10. Successful "on-demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors.
Corbingi A; Metafuni E; Di Salvatore M; Putzulu R; Chiusolo P; Schinzari G; Massini G; Rossi E; Zini G; Cassano A; Sica S; Piccirillo N
J Clin Apher; 2022 Feb; 37(1):65-69. PubMed ID: 34822725
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
12. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
[TBL] [Abstract][Full Text] [Related]
13. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
Gupta GK; Perreault S; Seropian SE; Tormey CA; Hendrickson JE
Transfus Apher Sci; 2021 Jun; 60(3):103069. PubMed ID: 33546988
[TBL] [Abstract][Full Text] [Related]
14. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Gregory KM; Rao KV; Armistead PM
Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
Ri M; Matsue K; Sunami K; Shimazaki C; Hayashi A; Sunaga Y; Sasaki T; Suzuki K
Int J Hematol; 2017 Oct; 106(4):562-572. PubMed ID: 28527129
[TBL] [Abstract][Full Text] [Related]
19. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
20. MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation.
Iida S; Ishida T; Miyamoto T; Teramukai S; Shirai H; Kanamori R; Tajima Y; Crawford B; Yi J; Teshima T
Int J Hematol; 2022 Sep; 116(3):411-422. PubMed ID: 35551631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
